Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Amyotrophic Lateral Sclerosis (ALS) Clinical Trials

100 recruiting trials for Amyotrophic Lateral Sclerosis (ALS). Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
100
Total Trials
100
Recruiting Now
1
Phase 3 Trials
10
Sponsors

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT05635266

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and...

Sponsor: Sanguine BiosciencesEnrolling: 200001 location
RECRUITINGNCT03225144

Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

Background: Neurodegenerative disorders can lead to problems in movement or memory. Some can cause abnormal proteins to build up in brain cells. Researchers want to understand...

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)Enrolling: 3601 location
RECRUITINGNCT06426030

Validation of Czech Language Versions of Questionnaires for ALS Patients' Functional Status and Biomarker Long-term...

Questionnaires and scales used to assess the clinical status and quality of life of patients with amyotrophic lateral sclerosis (ALS) are an important tool to monitor the disease...

Sponsor: Masaryk UniversityEnrolling: 1001 location
RECRUITINGNCT06528964

Proteinopathies Expression in Skin of Neurodegenerative Disorders

The goal of this observational study is to compare the aggregation pattern of proteinopathies (alpha-synuclein, amyloid-beta, phosphorylated tau and transactive response DNA...

Sponsor: Universidad Autonoma de San Luis PotosíEnrolling: 401 location
RECRUITINGNCT06441448

potentiALS - Quality of Life Among Patients With Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS) is a rapidly progressing and disabling disease with the majority of patients dying 3-5 years after symptom onset. Given the high symptom...

Sponsor: University of LeipzigEnrolling: 541 location
RECRUITINGNCT06828523

Assessing Perceptual Effects of Interactive Tasks

In this study, we will evaluate how solo, naive listeners perceive the speech of people with amyotrophic lateral sclerosis (ALS) and age-matched speakers produced across...

Sponsor: Penn State UniversityEnrolling: 13001 location
RECRUITINGNCT06363357

The Effect of a Muscle-mimicking, Fabric-type Shoulder Orthosis on Functional Movements of the Upper Limb in Patients...

The goal of this clinical trial is to investigate the effect of a muscle-mimicking, fabric-type shoulder orthosis on functional movements of the upper limb in patients with...

Sponsor: Seoul National University HospitalEnrolling: 301 location
RECRUITINGNCT07302321

Needs of ALS Patients With C9orf72 Mutation and Their Caregivers

Individuals with Amyotrophic Lateral Sclerosis (ALS) carrying the C9orf72 HRE mutation (C9Pos) often exhibit different phenotypic traits compared to other patients (C9Neg),...

Sponsor: Istituto Auxologico ItalianoEnrolling: 2083 locations
RECRUITINGNCT05663008

Impairments of Neuro-muscular Communication in Motor-Neuron Disease: A Bio-Marker for Early and Personalised Diagnosis

Motor neuron disease (MND) or ALS is a nervous system disease. ALS leads to a loss of movement ability that eventually leads to death. At the moment, there is no known treatment...

Sponsor: University of Dublin, Trinity CollegeEnrolling: 4001 location
RECRUITINGNCT06877143

Hypercaloric PEG Nutrition in ALS to Sustain Energy Homeostasis

Weight loss is a known negative prognostic factor in amyotrophic lateral sclerosis (ALS). Over the last years, various interventional studies targeting the energy deficit in ALS...

Sponsor: University of UlmEnrolling: 761 location
RECRUITINGNCT04715399

UPenn Observational Research Repository on Neurodegenerative Disease

The aim of this study is to create a repository of both cross-sectional and longitudinal data, including cognitive, linguistic, imaging and biofluid biological specimens, for...

Sponsor: University of PennsylvaniaEnrolling: 10001 location
RECRUITINGNCT06803784

Discovery and Validation of Protein Structural Complexes in Circulating Biofluids As Novel Biomarkers for Early...

Neurodegenerative disorders (NDDs), such as Parkinson¿s disease (PD), Alzheimer¿s disease (AD), Frontotemporal dementia (FTD) and Amyotrophic Lateral Sclerosis (ALS) are...

Sponsor: Neuromed IRCCSEnrolling: 1101 location
RECRUITINGNCT06266403

Evaluating Verbal Communication in Structured Interactions: Theoretical and Clinical Implications

The goal of this clinical trial is to learn about the effect of communicative interaction on verbal communication in people with amyotrophic lateral sclerosis (ALS) and...

Sponsor: Penn State UniversityEnrolling: 3001 location
RECRUITINGNCT07127172

GB-PRIME: An Early Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for the Control of...

The GB-PRIME Study is an early feasibility study designed to assess the clinical safety and functionality of the Neuralink N1 Implant and R1 Robot. This study involves...

Sponsor: Neuralink CorpEnrolling: 72 locations
RECRUITINGNCT05983211

Quantitative and Repetitive TMS in ALS - Recruiting for Stage 2

Stage 1 \[Enrolment closed\]: The goal of this open-label pilot clinical trial is to evaluate the safety and feasibility of accelerated, repetitive transcranial magnetic...

Sponsor: Sunnybrook Health Sciences CentreEnrolling: 151 location
RECRUITINGNCT07446114

Functional Outcomes and Control Using Synchron BCI - Canada

Functional Outcomes and Control Using Synchron BCI - Canada (FOCUS-CAN)

Sponsor: Synchron, Inc.Enrolling: 102 locations
RECRUITINGNCT06856850

Disease Biosignatures in ALS/FTD Spectrum: New Impactful Biological Perspectives Beyond Clinical Approaches

Diagnosis of ALS/FTD disease spectrum is challenging because it largely relies on clinical symptoms. Identifying novel biomarkers is essential for a paradigm shift towards a more...

Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaEnrolling: 2304 locations
RECRUITINGPhase 2 / Phase 3NCT04302870

Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial

MND-SMART is investigating whether selected drugs can slow down the progression of motor neuron disease (MND) and improve survival. The study is 'multi-arm' meaning more than one...

Sponsor: University of EdinburghEnrolling: 115020 locations
RECRUITINGNCT06021938

Alleviating Persistent Dyspnea in Amyotrophic Lateral Sclerosis Patients Treated With Non-Invasive Ventilation Through...

The evolution of amyotrophic lateral sclerosis (ALS) is marked by dyspnea, anxiety and pain, major determinants of suffering induced by this disease. The only palliative treatment...

Sponsor: Assistance Publique - Hôpitaux de ParisEnrolling: 351 location
RECRUITINGPhase 1NCT07118319

The Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With...

A Phase I Study to Assess the Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects with Amyotrophic Lateral Sclerosis

Sponsor: XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.Enrolling: 121 location
RECRUITINGNCT06668649

Polish Version Fatigue Severity Scale

Fatigue is one of main symptoms in multiple sclerosis, amyotrophic lateral sclerosis and other diseases with profound effect on quality of life and professional and social...

Sponsor: Jakub AntczakEnrolling: 3102 locations
RECRUITINGPhase 1NCT05279755

A Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of Prosetin in Healthy Volunteers and...

The primary purpose of this study is to evaluate the safety and tolerability of prosetin in healthy volunteers and participants with ALS.

Sponsor: ProJenXEnrolling: 724 locations
RECRUITINGNCT04406675

Social Cognition in Patients With Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis, also known as Charcot disease, is a neurodegenerative disease evidenced by gradual paralysis of the muscles involved in voluntary motor function....

Sponsor: University Hospital, AngersEnrolling: 741 location
RECRUITINGNCT05747937

Longitudinal Assessment of Autonomic and Sensory Nervous System in ALS

The goal of this interventional non-pharmacological study is to evaluate, using a multimodal approach, the progression of autonomic and sensory involvement in in amyotrophic...

Sponsor: Istituti Clinici Scientifici Maugeri SpAEnrolling: 1002 locations
RECRUITINGNCT06829212

Research on Wireless Brain Implant System for General Control of External Devices

The clinical trial aims to evaluate the safety and efficacy of the minimally invasive, wireless brain-machine interface system (WRS) in enabling general brain control of external...

Sponsor: Shanghai StairMed Technology Co., Ltd.Enrolling: 41 location
RECRUITINGNCT06681610

Testing Pulse Stimulation to Improve Motor Function in People With ALS: A Pilot Study

The goal of this clinical trial is to assess the efficacy of TPS of the motor cortex on biomarkers and clinical endpoints in patients with ALS. The main questions it aims to...

Sponsor: Parc de Salut MarEnrolling: 501 location
RECRUITINGNCT07213440

Identification of Early Markers for ALS

Although several molecules have been proposed as biomarker candidates, a clinically established signature for an early or even premotor diagnosis of ALS is not available. Due to...

Sponsor: Institut National de la Santé Et de la Recherche Médicale, FranceEnrolling: 601 location
RECRUITINGNCT04868994

Magnetic Imaging for Diagnostic of Amyotrophic Lateral Sclerosis

Nearly 60% of Amyotrophic Lateral Sclerosis (ALS) patients have a low level of diagnostic certainty (possible, probable) at the time of diagnosis. In the absence of biomarkers,...

Sponsor: University Hospital, ToulouseEnrolling: 501 location
RECRUITINGNCT07132879

Telehealth in MND-Research (TIM-R): A Research Database for MND

The aim of this study is to implement the Telehealth in MND system as a research database allowing people with MND to take part in research and provide data remotely...

Sponsor: University of SheffieldEnrolling: 10001 location
RECRUITINGNCT06249412

The Importance of Positive Expiratory Pressure Associated With the In-exsufflator in ALS Patients

Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disorder that impairs motor neurons, with a life expectancy of 2 to 7 years after diagnosis. ALS manifests as...

Sponsor: Groupe Hospitalier du HavreEnrolling: 111 location
RECRUITINGNCT06810219

Augmented Reality BCI Longitudinal Study for Persons With Late Stage ALS

The goal of this study is refine the usability of a BCI based communication platform. The study will take place in the greater Los Angeles area and will enroll up to 10...

Sponsor: CognixionEnrolling: 101 location
RECRUITINGNCT06581861

PREVENT ALL ALS Study

The ALL ALS Clinical Research Consortium is establishing research to collect a wide range of samples, clinical information and measurements from Amyotrophic Lateral Sclerosis...

Sponsor: St. Joseph's Hospital and Medical Center, PhoenixEnrolling: 60020 locations
RECRUITINGNCT05966038

ALS/MND Natural History Study Data Repository

This is a data repository for multi-site multi-protocol clinic-based Natural History Study of ALS and Other Motor Neuron Disorders (MND). All people living with ALS or other MNDs...

Sponsor: Massachusetts General HospitalEnrolling: 500016 locations
RECRUITINGNCT04097158

Biomarkers in Different Types of Amyotrophic Lateral Sclerosis (ALS) Patients Being Treated With Edaravone

This study is being conducted to help the investigators better understand how the new FDA approved medication Edaravone (also known as Radicava) works in subsets of patients with...

Sponsor: Loma Linda UniversityEnrolling: 1601 location
RECRUITINGNCT03217396

Biomarkers of Synaptic Damage in Multiple Sclerosis

A prospective and retrospective cohort study of about five years will be performed on blood and cerebrospinal fluid samples taken for diagnostic reasons from recruited patients...

Sponsor: Neuromed IRCCSEnrolling: 3001 location
RECRUITINGNCT07175935

Amyotrophic Lateral Sclerosis Registry in Thailand

This is a prospective, observational, multicenter registry designed to collect comprehensive clinical, genetic, and outcome data from patients diagnosed with amyotrophic lateral...

Sponsor: Chulalongkorn UniversityEnrolling: 1001 location
RECRUITINGNCT06649955

Controlling Amyotrophic Lateral Sclerosis Motor Neuron Excitability Study

Following completion of the ALS Early Feasibility Study of the MyoRegulator® device for treatment of ALS (NCT06165172), the CALM study will further assess the feasibility of the...

Sponsor: PathMaker Neurosystems Inc.Enrolling: 151 location
RECRUITINGNCT05819931

Breathing with Amyotrophic Lateral Sclerosis

The study aims to evaluate the effect of mechanical insufflator-exsufflator on the respiratory functions of Amyotrophic Lateral Sclerosis (ALS) patients evaluated via peak...

Sponsor: University Hospital, ToulouseEnrolling: 361 location
RECRUITINGPhase 2NCT07002034

RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in...

Sponsor: Reunion Neuroscience IncEnrolling: 10020 locations
RECRUITINGNCT06885918

ALS Research Collaborative

The goal of this natural history study is to learn more about the biological and clinical aspects of amyotrophic lateral sclerosis (ALS). This study's findings will help with drug...

Sponsor: ALS Therapy Development InstituteEnrolling: 20001 location
RECRUITINGNCT06881979

High-Tech Rehabilitation Pathway for Chronic Adult Neuromuscular Diseases - Fit4MedRob-Chronic MND Project

The primary objective is to demonstrate, in a population of chronic neuromuscular disease the non-inferiority of a rehabilitation treatment integrated with robotic and/or...

Sponsor: Istituti Clinici Scientifici Maugeri SpAEnrolling: 607 locations
RECRUITINGNCT04363684

ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390;...

Sponsor: Mayo ClinicEnrolling: 210020 locations
RECRUITINGNCT07085832

Assessment of Cardiopumonary Resuscitation (CPR) Competency Post ALS Course

to assess chest compression competency in healthcare providers following ALS training to identify areas for improvement and ensure high-quality CPR delivery.

Sponsor: National Hepatology & Tropical Medicine Research InstituteEnrolling: 3002 locations
RECRUITINGPhase 2NCT07161999

Study of COYA 302 for the Treatment of ALS

The ALSTARS trial will be conducted across 20-25 sites in the US and Canada, and will evaluate the safety and efficacy of an investigational treatment called COYA 302 for adults...

Sponsor: Coya TherapeuticsEnrolling: 12020 locations
RECRUITINGNCT07509125

Ultra-High Resolution PET in Aging, Neurodegeneration and Psychotic Disorders

The goal of this study is to use ultra-high-resolution (UHR) PET imaging to better understand how the brain and spinal cord change in healthy aging and in neurological and...

Sponsor: Universitaire Ziekenhuizen KU LeuvenEnrolling: 3001 location
RECRUITINGNCT06700304

CAN-PRIME: Precise Robotically Implanted Brain-Computer Interface for the Control of External Devices

The CAN-PRIME Study is to test the safety and functionality of Neuralink's N1 Implant and R1 Robot in people who have difficulty moving their arms and legs (tetraparesis or...

Sponsor: Neuralink CorpEnrolling: 61 location
RECRUITINGNCT03174938

The Swedish BioFINDER 2 Study

The Swedish BioFINDER 2 study is a new study that will launch in 2017 and extends the previous cohorts of BioFINDER 1 study (www.biofinder.se). BioFINDER 1 is used e.g. to...

Sponsor: Skane University HospitalEnrolling: 29502 locations
RECRUITINGNCT06203106

NYSCF Scientific Discovery Biobank

The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate diverse disease research using cells from the body (such as skin or blood...

Sponsor: New York Stem Cell Foundation Research InstituteEnrolling: 100001 location
RECRUITINGPhase 1NCT07193953

Intravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Disruption in Amyotrophic Lateral Sclerosis (ALS)

The goal of this study is to evaluate the safety and feasibility of IVIg administration in conjunction with primary motor cortex BBB opening using the Next Generation Dome Helmet...

Sponsor: Sunnybrook Health Sciences CentreEnrolling: 61 location
RECRUITINGPhase 1NCT06671236

Clinical Study of Regulatory T Cells (Tregs) in the Treatment of Neurodegenerative Diseases

An open, multi- center phase Ⅰ clinical study evaluating the safety and efficacy of autologous human polyclonal regulatory T cell injection (NP001 cell injection) in patients with...

Sponsor: Novabio TherapeuticsEnrolling: 121 location

Showing 50 of 100 trials.Search all Amyotrophic Lateral Sclerosis (ALS) trials

Frequently Asked Questions

There are currently 100 clinical trials for Amyotrophic Lateral Sclerosis (ALS), with 100 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Amyotrophic Lateral Sclerosis (ALS), review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 1 Phase 3 trials for Amyotrophic Lateral Sclerosis (ALS), representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice — always talk to your doctor about clinical trial participation.